Clinical features and posttreatment monitoring of dogs administered rivaroxaban (2018-2020): 19 cases
Tracy, A. L., Goggs, R., Brooks, M. B., & Lynch, A. M. (2022, April 20). JOURNAL OF VETERINARY EMERGENCY AND CRITICAL CARE, Vol. 4.
author keywords: anticoagulant; canine; thromboprophylaxis; venous thrombosis
MeSH headings : Animals; Anticoagulants; Clopidogrel / therapeutic use; Dog Diseases / drug therapy; Dogs; Factor Xa Inhibitors / therapeutic use; Humans; Retrospective Studies; Rivaroxaban / therapeutic use; Thrombosis / drug therapy; Thrombosis / veterinary
topics (OpenAlex): Venous Thromboembolism Diagnosis and Management; Blood Coagulation and Thrombosis Mechanisms; Cardiovascular Conditions and Treatments
TL;DR:
Dogs in this study received a range of rivaroxaban dosages and attained variable aXa values that were not directly correlated with dosage and there were also no significant differences in baseline clinicopathological variables in dogs in which a Xa fell within or outside this range.
(via
Semantic Scholar)
UN Sustainable Development Goal Categories
Sources: Web Of Science, NC State University Libraries, ORCID